Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Last Updated: 2026

Pharvaris

Rank#4378

Market Cap2.73B

CountryNetherlands

Summary

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

History

Pharvaris is a patient-driven biopharmaceutical company with an innovative methodology to unravel the complexity of auto-immune disorders. A pioneering approach to drug development that focuses on specifically targeting and understanding the underlying cause of auto-immune diseases has been the cornerstone of Pharvaris’ vision. Since its inception, the company has been making impressive strides in terms of scientific innovation and developing effective treatments.

Mission

Pharvaris is dedicated to advancing treatments for organ-specific auto-immune diseases that currently lack therapeutic options. We strive to leverage both scientific and business acumen, to develop better and safer treatments.

Vision

Pharvaris’ long-term goal is to become a global leader in the research, development, and commercialization of treatments for chronic rare auto-immune conditions.

References

https://in.investing.com/equities/pharvaris-bv

https://finance.yahoo.com/quote/PHVS/profile?p=PHVS

https://www.crunchbase.com/organization/pharvaris

https://companiesmarketcap.com/

https://pharvaris.com

Leadership team

Mr. Berndt Axel Edvard Modig CPA, M.B.A., MBA (Co-Founder, CEO & Exec. Director)

Ms. Anna Nijdam M.Sc., R.A. (Head of Fin. & Principal Accounting Officer)

Dr. Jochen Knolle Ph.D. (Chief Scientific Officer & COO)

Products / Services

Biotechnology, Life Science, Pharmaceutical

Address

Zug, Zug, Switzerland

Established

2015-01-01

Company Registration

SEC CIK number: 0001830487

Traded as

PHVS

Website

https://pharvaris.com

Social Media

Last Updated: 2026

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More

Last Updated: 2026

Pharvaris

Rank#4378

Market Cap2.73B

CountryNetherlands

Summary

History

Mission

Vision

Pharvaris’ long-term goal is to become a global leader in the research, development, and commercialization of treatments for chronic rare auto-immune conditions.

References

https://in.investing.com/equities/pharvaris-bv

https://finance.yahoo.com/quote/PHVS/profile?p=PHVS

https://www.crunchbase.com/organization/pharvaris

https://companiesmarketcap.com/

https://pharvaris.com

Leadership team

Mr. Berndt Axel Edvard Modig CPA, M.B.A., MBA (Co-Founder, CEO & Exec. Director)

Ms. Anna Nijdam M.Sc., R.A. (Head of Fin. & Principal Accounting Officer)

Dr. Jochen Knolle Ph.D. (Chief Scientific Officer & COO)

Products / Services

Biotechnology, Life Science, Pharmaceutical